HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Novel Approaches Make Headway in HER2+ Metastatic Breast Cancer

August 1st 2019

Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

July 19th 2019

Michel Velez, MD, provides perspective on the clinical experience with neratinib in patients with early-stage HER2-positive breast cancer as well as promising data that may lead to an indication in the metastatic setting.

Expert Explains Evolution of De-Escalating Therapies in HER2+ Breast Cancer

July 19th 2019

Keerthi Gogineni, MD, MSHP, discusses several trials in the breast cancer field, specifically looking at de-escalation therapies.

Neratinib Approved in Canada for Early-Stage HER2+ Breast Cancer

July 17th 2019

Health Canada has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early-stage, hormone receptor–positive, HER2-overexpressed/amplified breast cancer within 1 year after completing trastuzumab (Herceptin)-based adjuvant therapy.

Dr. Velez on Managing Neratinib-Associated Diarrhea in HER2+ Breast Cancer

July 12th 2019

Michel Velez, MD, medical oncologist at Holy Cross Hospital, discusses the management of neratinib (Nerlynx)-associated diarrhea in patients with early-stage HER2-positive breast cancer.

FDA Approval Sought for Neratinib Combo in HER2+ Breast Cancer

July 1st 2019

An application has been submitted to the FDA for neratinib for use in combination with capecitabine for the third-line treatment of patients with HER2-positive metastatic breast cancer.

Incorporating Neoadjuvant and Adjuvant Data in Early-Stage HER2+ Breast Cancer

June 26th 2019

Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.

Surgery Shows Potential Survival Benefit in Metastatic HER2+ Breast Cancer

June 25th 2019

Ross Mudgway, discusses the importance of considering surgery for patients with stage IV HER2-positive breast cancer and addresses disparities in healthcare among different social groups.

Dr. Rugo on Unmet Needs Beyond Second-Line Treatment in HER2+ Breast Cancer

June 21st 2019

Dr. Cobleigh on the Focus of Future Research in HER2+ Breast Cancer

June 11th 2019

Melody A. Cobleigh, MD, a professor of medical oncology at Rush University Medical Center, discusses the focus of future research in HER2-positive breast cancer.

Dr. Cheng on the Role of T-DM1 in HER2+ Breast Cancer

June 5th 2019

Yee Chung Cheng, MD, associate professor of medicine, Medical College of Wisconsin, discusses the role of T-DM1 in patients with HER2-positive breast cancer.

Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer

June 4th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the phase III SOPHIA trial of margetuximab plus chemotherapy versus trastuzumab (Herceptin) plus capecitabine in patients with HER2-positive metastatic breast cancer after prior anti–HER2-targeted therapies.

Dr. Mortimer on Brain Metastases in HER2+ Breast Cancer

May 24th 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

Dr. Nye on Neratinib-Associated Diarrhea in HER2+ Breast Cancer

May 21st 2019

Lauren Nye, MD, assistant professor, University of Kansas Medical Center, discusses the concern of neratinib-associated diarrhea in patients with HER2-positive breast cancer.

Expert Highlights Latest Advances, Next Steps in HER2+ Breast Cancer

May 9th 2019

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

[Fam-] Trastuzumab Deruxtecan Elicits Responses in Advanced HER2+ Breast Cancer

May 8th 2019

The antibody-drug conjugate [fam-] trastuzumab deruxtecan (DS-8201) demonstrated encouraging responses in patients with unresectable and/or metastatic HER2-positive breast cancer that has been previously treated with ado-trastuzumab emtansine, according to topline findings from the phase II DESTINY-BreastO1 study.

FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer

May 4th 2019

The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.

Dr. Mortimer on Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

May 3rd 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

New VENTANA HER2 ISH DNA Assay Launches for Breast, Gastric Cancers

April 23rd 2019

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Landmark Approvals Lead to Continual Progress in HER2+ Breast Cancer

April 18th 2019

Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.